STELLA, LEONARDO
 Distribuzione geografica
Continente #
NA - Nord America 548
AS - Asia 542
EU - Europa 423
Continente sconosciuto - Info sul continente non disponibili 72
AF - Africa 45
SA - Sud America 37
OC - Oceania 3
Totale 1.670
Nazione #
US - Stati Uniti d'America 483
IT - Italia 260
BD - Bangladesh 182
SG - Singapore 97
CN - Cina 94
DE - Germania 68
VN - Vietnam 63
EG - Egitto 35
IN - India 34
CA - Canada 28
HK - Hong Kong 28
BR - Brasile 24
FR - Francia 22
NL - Olanda 19
MX - Messico 15
ES - Italia 12
JP - Giappone 12
GB - Regno Unito 11
PL - Polonia 11
CR - Costa Rica 7
PK - Pakistan 5
HU - Ungheria 4
IQ - Iraq 4
JM - Giamaica 4
RO - Romania 4
TR - Turchia 4
UA - Ucraina 4
AU - Australia 3
CO - Colombia 3
EC - Ecuador 3
GT - Guatemala 3
KR - Corea 3
ZA - Sudafrica 3
AR - Argentina 2
BM - Bermuda 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ID - Indonesia 2
IE - Irlanda 2
KE - Kenya 2
KG - Kirghizistan 2
MA - Marocco 2
MY - Malesia 2
NI - Nicaragua 2
PE - Perù 2
TT - Trinidad e Tobago 2
AE - Emirati Arabi Uniti 1
AZ - Azerbaigian 1
BG - Bulgaria 1
BO - Bolivia 1
CH - Svizzera 1
CL - Cile 1
EE - Estonia 1
HN - Honduras 1
JO - Giordania 1
LB - Libano 1
LT - Lituania 1
OM - Oman 1
PA - Panama 1
PH - Filippine 1
SA - Arabia Saudita 1
TH - Thailandia 1
TN - Tunisia 1
TW - Taiwan 1
UZ - Uzbekistan 1
VE - Venezuela 1
Totale 1.598
Città #
Ashburn 82
Frankfurt am Main 62
San Jose 54
Singapore 32
Hong Kong 28
New York 28
Rome 25
Council Bluffs 24
Ho Chi Minh City 21
Al Mansurah 20
Los Angeles 18
Milan 18
Buffalo 15
Kolkata 15
Naples 14
Santa Clara 14
Cairo 13
Hanoi 13
Hillsboro 13
Dallas 11
Tokyo 11
Toronto 11
Boardman 10
Princeton 10
Beijing 9
Mexico City 8
Madrid 7
Verona 7
Warsaw 7
Amsterdam 6
Bologna 6
Orem 6
Agropoli 5
Bari 5
Catania 5
Genoa 5
San José 5
Chennai 4
Figino 4
Indore 4
Limburg an der Lahn 4
Palermo 4
Abbeville 3
Brescia 3
Budapest 3
Da Nang 3
Florence 3
Lucca 3
Ottawa 3
Phoenix 3
Phủ Lý 3
Queens 3
Richmond 3
Zhengzhou 3
Atlanta 2
Bishkek 2
Brisbane 2
Bắc Giang 2
Bắc Ninh 2
Cagliari 2
Can Tho 2
Charlotte 2
Denver 2
Faisalabad 2
Fresno 2
Gadsden 2
Hamilton 2
Kansas City 2
Karachi 2
Kingston 2
Las Vegas 2
Managua 2
Miami 2
Montreal 2
Newark 2
Norman 2
Oakland 2
Padua 2
Pasadena 2
Philadelphia 2
Pittsburgh 2
Port Moody 2
Portsmouth 2
Stoughton 2
São Paulo 2
Taboão da Serra 2
Tacoma 2
Turin 2
Wroclaw 2
Abu Dhabi 1
Aga 1
Ahmedabad 1
Albuquerque 1
Alto Araguaia 1
Amman 1
Anderson 1
Andria 1
Apizaco 1
Apple Valley 1
Aubrey 1
Totale 780
Nome #
PO5-18-YI Predictors of esophago-gastric varices and variceal bleeding in patients receiving atezolizumab/bevacizumab for unresectable hepatocellular carcinoma 88
PO5-12-YI Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab-Bevacizumab for hepatocellular carcinoma 84
OP034 LIVER DECOMPENSATION AS A NEW OUTCOME AND PROGNOSTIC INDICATOR IN CIRRHOTIC PATIENTS WITH HEPATOCELLULAR CARCINOMA TREATED WITH ATEZOLIZUMAB PLUS BEVACIZUMAB: A REAL-LIFE MULTICENTER STUDY 70
Hepatitis C Eradication Improves Oncologic and Clinical Outcomes in Patients Treated With Atezolizumab Plus Bevacizumab 61
Manuale di malattie infettive e microbiologia. SSM 2026 58
COVID-19 atypical Parsonage-Turner syndrome: a case report 53
Thrombotic Risk and Coagulation Imbalance in Cirrhosis and Hepatocellular Carcinoma: Clinical Implications and Management 53
PO3-23-YI The changing epidemiology of patients with HCC receiving a first-line systemic therapy: insights from ARPES and ARTE databases (2008- 2024) 50
PO4-03-YI Efficacy and safety of atezoliumab/bevacizumab for hepatocellular carcinoma in a real-world prospective cohort: a 2024 update 49
PO6-11 Statins in patients with advanced HCC treated with atezolizumab/bevacizumab: a propensity score-matched cohort analysis from ARTE an Italian prospective multicentric dataset 48
PP0819 HEPATITIS C TREATMENT IMPROVES ONCOLOGIC OUTCOMES IN PATIENTS RECEIVING ATEZOLIZUMAB PLUS BEVACIZUMAB 48
Conversion Ability of Immunotherapy in Hepatocellular Carcinoma: Insights from the International Converse Study 42
Autobrewery Syndrome and Endogenous Ethanol Production in Patients with MASLD: A Perspective from Chronic Liver Disease 40
Cancer Vaccines: A Promising Therapeutic Strategy in Advanced Solid Tumors 39
Incidence of deep vein thrombosis among non‐ICU patients hospitalized for COVID‐19 despite pharmacological thromboprophylaxis 38
Asthma in patients admitted to emergency department for COVID-19: prevalence and risk of hospitalization 36
OC.03.3 COMPARATIVE ANALYSIS OF ATEZOBEV’S THERAPEUTIC EFFICACY IN ADVANCED HEPATOCELLULAR CARCINOMA AMONG NON-CIRRHOTIC PATIENTS: FINDINGS FROM A RETROSPECTIVE MULTICENTER STUDY 35
Angiotensin‐converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID‐19 34
Functional hypothalamic amenorrhea: gut microbiota composition and the effects of exogenous estrogen administration 32
Malnutrition in COVID-19 survivors: prevalence and risk factors 32
PO7-09-YI Does AtezoBev present as a safe and efficacious treatment option for hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicentric real-world study 31
Risk of burnout and stress in physicians working in a COVID team: A longitudinal survey 30
Management of Portal Hypertension in Patients with Hepatocellular Carcinoma on Systemic Treatment: Current Evidence and Future Perspectives 28
COVID-19 and intestinal inflammation: Role of fecal calprotectin 28
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 27
Intestinal Inflammation and Permeability in Patients Recovered from SARS-CoV-2 Infection 27
Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment 24
The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence 24
Assessment of neurological manifestations in hospitalized patients with COVID‐19 23
Outcomes and safety of DAA treatment in HCV cirrhotic patients treated with Atezolizumab- Bevacizumab for hepatocellular carcinoma 22
Post-COVID-19 global health strategies: the need for an interdisciplinary approach 21
Persistent Symptoms in Patients After Acute COVID-19 20
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 20
Liver involvement is not associated with mortality: results from a large cohort of SARS‐CoV‐2‐positive patients 19
Hepatocellular-Carcinoma-Derived Organoids: Innovation in Cancer Research 19
Letter: prevalence and patterns of gastrointestinal symptoms in a large Western cohort of patients with COVID-19 18
Predicting In‐Hospital Mortality in COVID‐19 Older Patients with Specifically Developed Scores 18
Manuale di malattie infettive e microbiologia. Concorso Nazionale SSM 18
Etiology of Hepatocellular Carcinoma May Influence the Pattern of Progression under Atezolizumab-Bevacizumab 18
Liver cirrhosis in the Emergency Department: a change of paradigm in DAAs era 17
Can AtezoBev be a safe and effective option for treating hepatocellular carcinoma in patients with Child-Pugh B cirrhosis? A retrospective multicenter real-world study 17
Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications 16
Heparanase-1 and MMPs in Covid-19 and non-Covid-19 pneumonia 16
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results 15
Derivation and validation of a scoring system to assess pre-test probability of being COVID-19 positive 14
THU-492 Prognostic significance of liver decompensation, liver function and portal hypertension in cirrhotic patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab 14
Role of Gut Microbial Metabolites in the Pathogenesis of Primary Liver Cancers 14
Neuropsychological Measures of Long COVID-19 Fog in Older Subjects 13
Liver Decompensation in Patients With Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Real-life Study 13
Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice 13
The diagnosis of neglected tropical diseases (NTDs) in Italy: reply 12
Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection 11
Psychological Distress After Covid-19 Recovery: Reciprocal Effects With Temperament and Emotional Dysregulation. An Exploratory Study of Patients Over 60 Years of Age Assessed in a Post-acute Care Service 11
Peripapillary Retinal Vascular Involvement in Early Post-COVID-19 Patients 9
Residual respiratory impairment after COVID-19 pneumonia 9
Spectrum and burden of neglected tropical diseases observed in an infectious and tropical diseases unit in Florence, Italy (2000–2015) 9
Retinal capillary involvement in early post-COVID-19 patients: a healthy controlled study 8
Seroprevalence of anti‐SARS‐CoV‐2 IgG antibodies in children with household exposure to adults with COVID‐19: Preliminary findings 7
Neuropsychological measures of post-COVID-19 cognitive status 7
Totale 1.670
Categoria #
all - tutte 7.778
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.778


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2025/20261.345 0 0 0 0 266 121 67 158 129 201 163 240
2026/2027325 81 101 57 86 0 0 0 0 0 0 0 0
Totale 1.670